Virtual Library
Start Your Search
J.M. Sands
Author of
-
+
P1.06 - Epidemiology/Primary Prevention/Tobacco Control and Cessation (ID 692)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Epidemiology/Primary Prevention/Tobacco Control and Cessation
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.06-017 - Lung Cancer Detection Rates for National Comprehensive Cancer Network Group 2 High Risk Individuals (ID 9982)
09:30 - 09:30 | Author(s): J.M. Sands
- Abstract
Background:
Lung cancer screening with LDCT scan is covered by private insurance and Medicare for current and former smokers quit within the last 15 years, age 55 to 77 (55-80 for private insurance), with a 30 or greater pack year smoking history. However, it is not covered for National Comprehensive Cancer Network (NCCN) Group 2; a group of slightly younger, lighter smokers with no limit on quit duration but at least one additional risk factor. Our previous study on 1328 patients demonstrated NCCN Group 2 (Cohort A) to be at equivalent risk for lung cancer as the covered group (Cohort B). The objective of this study is to statistically evaluate the potential difference in lung cancer prevalence between Cohorts A and B. Towards that end we are compiling a large sample set (1563 Cohort A, 4000 Cohort B) with 80% power that can detect a minimum of 1% difference in lung cancer prevalence between the two groups.
Method:
A REDCap data registry was created to retrospectively collect LDCT scan data on high-risk individuals from two historical cohorts who underwent lung cancer screening at three institutions between January 1, 2012 and May 31, 2017.
Result:
To date, 804 Cohort A and 2712 Cohort B individuals have been entered into the data registry. Data entry is expected to be complete by the end of 2017 with follow-up through end of May 2019 to ensure a minimum follow up period of two years for each patient. A preliminary analysis is planned with 3 month minimum follow-up. A separate analysis of overall cancer detection rates (CDR) with a smaller sample at one of the study institutions shows CDR are not statistically different between the two cohorts (Pearson’s Chi-Square). The CDR for Cohort A, the NCCN Group 2 patients, was 3.98% (28 lung cancers in 704 patients) and in Cohort B, the covered group, was 3.92% (91 lung cancers in 2319 patients; p=0.95). Average time in the program was 2.5 years for Cohort A and 2.4 years for the Cohort B (p=0.18). Maximum time in the program was 5.4 years for both groups; minimum follow-up time was 3 months.
Conclusion:
Using an expanded data set, NCCN Group 2 CDR continue to be the same as the group covered by Medicare and insurance. At this point, there is no statistical difference in lung cancer risks between the two groups.
